Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Charts of the Day: The States of U.S. Gambling
A bit of context to simmer on following the big deal between Caesars and Eldorado.
Prohibition and the Paradoxical Proclivity of Cannabis Consumption
Is prohibition the real factor propping up projections for demand and pricing in the cannabis market?
Can Oracle Retake Lost Market Share -- Or Is It In the Clouds?
Oracle tells investors it can regain the crown it once held among enterprises and end-users, but some aren't so sure.
Wall Street Is Still Waiting on the Oracle Debate to Settle
Is the bad news for Oracle all over?
Tencent-Backed WeDoctor Scraps International Listing for Shanghai
The healthcare app creator reportedly shelves a Hong Kong listing in favor of "China's Nasdaq" due to data privacy and transparency concerns.
Slack Marches to the Beat of a Different Drum in Unicorn Parade
Will Slack help set a new trend for IPO strategy among red-hot technology companies?
Is Facebook's Blockchain Bet the Next Big Thing in Big Tech?
Is Libra the next tectonic shift in tech? Is it even a cryptocurrency at all?